Jason Rytlewski, MD
Clinical Cardiac Electrophysiology · Columbia, MONPI 1104036029
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Biotronik Inc. at 56.0% of the total. Reporting peaked in 2019 at $8,124 and has fallen 53.7% since, to $3,759 in 2025.
Across 462 payments — averaging $73.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$19K
- Medtronic$7K
- Biosense Webster, Inc.$2K
- Medical Device Business Services, Inc.$1K
- Boston Scientific$1K
- Abbott$975
- plus $2K from 21 others
Across 2 payments — averaging $1768.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$4K
What the payments were for
- Consulting fees$5,54316%
- Speaking & faculty fees$6,20018%
- Travel & lodging$7,64523%
- Food & beverage$14,44143%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 110 | $19,005 |
| Medtronic(2 entities) | 113 | $7,095 |
| Biosense Webster, Inc. | 73 | $1,995 |
| Medical Device Business Services, Inc. | 5 | $1,335 |
| Boston Scientific | 56 | $1,334 |
| Abbott | 19 | $975 |
| Atricure, Inc. | 6 | $612 |
| E.r. Squibb & Sons, L.L.C. | 11 | $196 |
| Amgen | 11 | $188 |
| Sanofi-aventis U.S. LLC | 4 | $163 |
| AstraZeneca | 10 | $147 |
| Novartis | 8 | $136 |
| Acutus Medical, Inc. | 1 | $122 |
| Cardiva Medical, Inc. | 4 | $92 |
| Pfizer | 5 | $84 |
| Boehringer Ingelheim | 4 | $78 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $61 |
| Merck | 3 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $45 |
| Edwards Lifesciences | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $30 |
| Johnson & Johnson | 2 | $28 |
| Astellas Pharma US Inc | 1 | $23 |
| Novo Nordisk | 1 | $17 |
| Heartflow, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BioMonitor$2,007
- TYRX$2,000
- Carto 3$1,700
- Acticor 7 VR-T DX$1,281
- Rivacor 7 DR-T$1,117
- Edora 8 DR-T$991
- Solia$973
- ENSITE PRECISION$554
- OCTARAY MAPPING CATHETER$542
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$504
- Viva$403
- Advisa$391
- EVERA MRI XT DR SURESCAN$344
- AURORA EV-ICD MRI SURESCAN$264
- Edora$255
- Acticor$255
- Rivacor$255
- AMVIA EDGE$139
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$132
- WATCHMAN FLX$105
How this compares
$33,930 in reported general payments places this provider in the 75th percentile of 74 clinical cardiac electrophysiology providers in Missouri.
See all clinical cardiac electrophysiology providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 307 | $260,042 |
| XareltoRivaroxaban | 91 | $79,646 |
| EntrestoSacubitril/Valsartan | 55 | $58,912 |
| Dofetilide | 24 | $5,393 |
| Amiodarone Hcl | 95 | $2,030 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 70 | $1,782 |
| Carvedilol | 244 | $1,309 |
| Midodrine Hcl | 21 | $1,007 |
| SotalolSotalol Hcl | 64 | $997 |
| Bisoprolol Fumarate | 14 | $946 |
| Metoprolol Succinate | 50 | $926 |
| Atorvastatin Calcium | 69 | $670 |
| Potassium Chloride | 30 | $665 |
| Metoprolol Tartrate | 73 | $460 |
| Furosemide | 89 | $452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $84 | $260,042307 claims |
| Johnson & JohnsonXarelto | $28 | $79,64691 claims |
| NovartisEntresto | $136 | $58,91255 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 74 clinical cardiac electrophysiology providers in Missouri.
Other clinical cardiac electrophysiology in Columbia
- Rahul JainColumbia$10K
- John VerbskyColumbia$8K
- Hemant GodaraColumbia$7K
- Dan PierceColumbia$5K
- Greg FlakerColumbia$4K
- Zhenguo LiuColumbia$3K
- Phillip CuculichSaint Louis$473K
- Sanjaya GuptaKansas City$316K
- Daniel CooperSaint Louis$168K
- Jessica KlineKansas City$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.